STOCK TITAN

SBC Medical Group Holdings Announces Definitive Agreement to Acquire, Aesthetic Healthcare Holdings Pte. Ltd, a Multi-Unit Owner of Aesthetic Treatment Clinics in Singapore

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Positive)

SBC Medical Group Holdings (Nasdaq: SBC) has announced a definitive agreement to acquire Aesthetic Healthcare Holdings (AHH), a Singapore-based aesthetic medical treatment provider, in an all-cash transaction set to close on November 13, 2024. AHH operates 21 outlets across four brands in Singapore. This acquisition marks SBC's first step in its international expansion strategy, focusing on U.S. and Asian markets. Singapore was chosen as the hub for Asian operations due to its strategic location and developed medical infrastructure. The Asian aesthetic medical market shows an 11% annual growth rate, representing the second-largest share globally.

SBC Medical Group Holdings (Nasdaq: SBC) ha annunciato un accordo definitivo per acquisire Aesthetic Healthcare Holdings (AHH), un fornitore di trattamenti estetici con sede a Singapore, in una transazione interamente in contante che si prevede si concluderà il 13 novembre 2024. AHH gestisce 21 punti vendita attraverso quattro marchi a Singapore. Questa acquisizione segna il primo passo di SBC nella sua strategia di espansione internazionale, concentrandosi sui mercati statunitensi e asiatici. Singapore è stata scelta come hub per le operazioni asiatiche grazie alla sua posizione strategica e all'infrastruttura medica sviluppata. Il mercato della medicina estetica in Asia mostra un tasso di crescita annuale dell'11%, rappresentando la seconda quota più grande a livello globale.

SBC Medical Group Holdings (Nasdaq: SBC) ha anunciado un acuerdo definitivo para adquirir Aesthetic Healthcare Holdings (AHH), un proveedor de tratamientos médicos estéticos con sede en Singapur, en una transacción completamente en efectivo que se cerrará el 13 de noviembre de 2024. AHH opera 21 puntos de venta en cuatro marcas en Singapur. Esta adquisición marca el primer paso de SBC en su estrategia de expansión internacional, enfocándose en los mercados de EE. UU. y Asia. Se eligió a Singapur como centro para las operaciones asiáticas debido a su ubicación estratégica y su infraestructura médica desarrollada. El mercado de medicina estética en Asia muestra una tasa de crecimiento anual del 11%, representando la segunda participación más grande a nivel mundial.

SBC Medical Group Holdings (Nasdaq: SBC)는 싱가포르에 본사를 둔 미용 의료 치료 제공업체인 Aesthetic Healthcare Holdings (AHH)를 인수하는 최종 합의에 도달했다고 발표했다. 이 거래는 현금 전액 거래로 2024년 11월 13일에 마감될 예정이다. AHH는 싱가포르에서 네 개 브랜드를 통해 21개의 매장을 운영하고 있다. 이번 인수는 SBC의 국제 확장 전략의 첫 번째 단계로, 미국과 아시아 시장에 집중하고 있다. 아시아 운영의 허브로 싱가포르가 선택된 것은 전략적 위치와 발전된 의료 인프라 덕분이다. 아시아의 미용 의료 시장은 연평균 11%의 성장률을 보이고 있으며, 이는 전 세계에서 두 번째로 큰 비중을 차지하고 있다.

SBC Medical Group Holdings (Nasdaq: SBC) a annoncé un accord définitif pour acquérir Aesthetic Healthcare Holdings (AHH), un fournisseur de traitements esthétiques basé à Singapour, dans le cadre d'une transaction entièrement en espèces prévue pour se clore le 13 novembre 2024. AHH opère 21 points de vente sous quatre marques à Singapour. Cette acquisition marque le premier pas de SBC dans sa stratégie d'expansion internationale, axée sur les marchés américain et asiatique. Singapour a été choisi comme plaque tournante pour les opérations asiatiques en raison de sa position stratégique et de son infrastructure médicale développée. Le marché de la médecine esthétique en Asie affiche un taux de croissance annuel de 11 %, représentant la deuxième plus grande part au niveau mondial.

SBC Medical Group Holdings (Nasdaq: SBC) hat eine endgültige Vereinbarung zur Übernahme von Aesthetic Healthcare Holdings (AHH), einem in Singapur ansässigen Anbieter ästhetischer medizinischer Behandlungen, bekannt gegeben. Diese Transaktion erfolgt vollständig in bar und soll am 13. November 2024 abgeschlossen werden. AHH betreibt 21 Filialen unter vier Marken in Singapur. Diese Übernahme stellt den ersten Schritt von SBC in seiner internationalen Expansionsstrategie dar, die sich auf die Märkte in den USA und Asien konzentriert. Singapur wurde als Zentrum für die asiatischen Aktivitäten ausgewählt, aufgrund seiner strategischen Lage und der entwickelten medizinischen Infrastruktur. Der asiatische Markt für ästhetische Medizin zeigt eine jährliche Wachstumsrate von 11% und repräsentiert den zweitgrößten Anteil weltweit.

Positive
  • Strategic acquisition of 21 outlets across 4 brands in Singapore
  • Entry into Asia's fast-growing aesthetic medical market (11% annual growth rate)
  • Expansion of global presence through established brand recognition
  • Access to Singapore's strategic location as gateway to Asian markets
  • Addition of AHH's existing customer base to SBC network
Negative
  • Cash expenditure for acquisition may impact short-term liquidity
  • Integration risks of merging different corporate cultures
  • Regulatory compliance challenges in new market

Insights

This strategic acquisition marks a significant expansion move for SBC Medical Group. The all-cash purchase of Aesthetic Healthcare Holdings (AHH) brings 21 outlets and four established brands under SBC's control, providing instant market penetration in Singapore's lucrative aesthetic medicine market. The Asian aesthetic medical market's 11% annual growth rate makes this acquisition particularly valuable.

The deal offers three key advantages: 1) Immediate revenue diversification through AHH's established customer base, 2) Strategic positioning in Singapore as a gateway to broader Asian expansion and 3) Potential operational synergies through shared medical technologies and management expertise. The acquisition aligns with SBC's international growth strategy, particularly targeting U.S. and Asian markets.

This transaction represents a significant milestone in SBC's expansion strategy, though financial terms were not disclosed. The market's response will largely depend on the acquisition price and integration execution.

Singapore's strategic position in the aesthetic medicine market makes this acquisition particularly compelling. The country's robust medical infrastructure, regulatory environment and growing affluent population provide an ideal foundation for regional expansion. AHH's established presence under Dr. Ewen Chee's leadership brings credibility and local market expertise.

The timing aligns with increasing disposable income trends in Asia and growing demand for aesthetic treatments. With Asia representing the second-largest share of the global aesthetic medical market, this acquisition positions SBC to capture significant market share in a high-growth region. The multi-brand strategy of AHH allows for market segmentation and broader customer reach, which could accelerate SBC's regional penetration.

Aesthetic Healthcare establishes bridgehead for expansion into Asia and accelerate SBC’s presence in global markets

SBC to leverage operational synergies and implement growth strategies to launch into new verticals and geographies

TOKYO--(BUSINESS WIRE)-- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”, or the “Company”, or “SBC”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that it has entered into a definitive agreement to acquire Aesthetic Healthcare Holdings Pte. Ltd. ("AHH"), a privately-held Singapore-based company that owns and operates several brands that provide aesthetic medical treatments in an all cash transaction scheduled to close on November 13, 2024.

SBC to leverage operational synergies and implement growth strategies to launch into new verticals and geographies (Graphic: Business Wire)

SBC to leverage operational synergies and implement growth strategies to launch into new verticals and geographies (Graphic: Business Wire)

The acquisition by SBC of AHH marks the first step in Company’s strategy to grow its business through acquisitions, which includes plans to expand its business internationally with a primary focus on the U.S. and Asia markets. The Company believes Singapore represents the ideal hub for the further development of its brand in the region.

Strategic Rationale: A foothold to expand into Asia
Founded by Dr. Ewen Chee, a pioneer in Singapore's aesthetic medical industry, AHH is well established in the country with a multi-brand strategy that caters to diverse customer needs. With the acquisition of AHH, SBC believes it has taken an important step toward expanding its presence in the Asian market. AHH's portfolio consists of four brands and 21 outlets, and will be added to the SBC clinic network, strengthening its customer base in the Asian region. SBC has positioned Singapore as the core of its Asian operations and plans to leverage the high brand recognition AHH has established to promote strategic partnerships throughout Asia. The expansion of SBC's global presence is consistent with its mission to establish leadership in the aesthetic medical industry by providing the value of beauty and health beyond national borders through innovative aesthetic medical treatments.

Strategies to Expand the Aesthetic Medicine Market by Leveraging Singapore's Advantages
As disposable income increases in line with recent economic growth, demand for aesthetic medical treatments to maintain youth and beauty is growing rapidly. The Asian market in particular has shown remarkable growth, and currently accounts for the second largest share of the global aesthetic medical market, with an average annual growth rate of 11%*, exceeding that of any other region. Among these, Singapore is ideally positioned as a gateway to the Asian market due to its geographical and cultural advantages, and with its well-developed medical infrastructure and regulatory environment. SBC believes it is an ideal base for expanding services throughout Asia.
*Data Source: https://straitsresearch.com/report/aesthetic-medicine-market

Dr. Ewen Chee, Chief Executive Officer of Aesthetic Healthcare Holdings Pte. Ltd., said:
“We are pleased to announce that our clinic group has become a member of SBC, one of the leading aesthetic medical clinic groups in Japan. Since our establishment, we have been committed to providing the best medical treatments to each and every patient in Singapore, and have earned the trust of many customers. We would like to express our deepest gratitude to our employees and patients for their support. We see this acquisition as an opportunity for new growth, and we are confident that SBC's advanced technology, management know-how, and extensive experience in the Japanese market will contribute greatly to our further development. We expect to accelerate our expansion throughout Asia and provide the best aesthetic medical treatments to as many patients as possible. We also hope to contribute to the expansion of the franchise business in the U.S. by utilizing the franchise business know-how we have cultivated through the operation of SkinGo! Together, with SBC, we aim to be a leader in the Asian aesthetic medicine industry and will make further efforts to meet the expectations of each and every patient.”

Yoshiyuki Aikawa
Founder and Chief Executive Officer of SBC Medical Group Holdings, Inc., said:
“We are very pleased to welcome AHH to our group. AHH has been providing high-quality aesthetic medical services in Singapore for many years and has earned the trust of many customers. With this acquisition, we expect to accelerate our expansion into the Asian market and strengthen our global aesthetic medical treatment delivery system. We are confident that we can create significant synergies by combining expertise in aesthetic medical treatments and management know-how we have cultivated in Japan with AHH's brand power and customer base. We intend to grow together while respecting the corporate culture that AHH has cultivated thus far. We will also respect the culture and customs of Singapore and try to manage the company in a way that is rooted in the local community, while actively contributing to the local community. By leveraging the strengths of both companies, we aim to become a leading aesthetic medical clinic in Asia.”

------------------------------------------------------------------------------------------

About SBC Medical
SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic’s customer rewards program (customer loyalty point program), and payment tools for the franchisee clinics.
For more information, visit https://sbc-holdings.com/  

About Aesthetic Healthcare Holdings Pte. Ltd.
AHH is based in Singapore and operates aesthetic medical clinics, family clinics, and quick facial aesthetics outlets. The founder, Dr. Ewen Chee, is known as one of the pioneers in the field of aesthetic medicine in Singapore and is a co-chair of the first Asia Pacific Thread Lift Conference (APEM) and a board-certified physician by the American Academy of Aesthetic Medicine. He is a frequent speaker at international conferences and workshops, and his expertise and knowledge have been featured in numerous scientific publications.

Major brands and number of clinics:

Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company’s beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company’s control. These forward-looking statements reflect the Company’s current views with respect to, among other things, the Company’s product launch plans and strategies; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” “targets” or “hopes” or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management’s current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading “Risk Factors” and elsewhere in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov.

SBC Medical Group Holdings Incorporated

Hikaru Fukui / Head of Investor Relations

e-mail: ir@sbc-holdings.com

Source: SBC Medical Group Holdings Incorporated

FAQ

When will SBC Medical Group complete the acquisition of Aesthetic Healthcare Holdings?

The acquisition is scheduled to close on November 13, 2024.

How many outlets does Aesthetic Healthcare Holdings operate that SBC is acquiring?

AHH operates 21 outlets across four brands in Singapore.

What is the growth rate of the Asian aesthetic medical market where SBC is expanding?

The Asian aesthetic medical market has an average annual growth rate of 11%, making it the second-largest share of the global market.

Why did SBC choose Singapore for its Asian expansion?

SBC chose Singapore due to its strategic geographical location, cultural advantages, well-developed medical infrastructure, and regulatory environment.

SBC Medical Group Holdings Incorporated

NASDAQ:SBC

SBC Rankings

SBC Latest News

SBC Stock Data

639.90M
1.48M
98.56%
0.29%
0.03%
Consulting Services
Services-offices & Clinics of Doctors of Medicine
Link
United States of America
IRVINE